Get to know our clinical trials
Trial of MK-1942 in participants with dementia due to Alzheimer's disease
IN THIS TRIAL MK-1942 IS BEING EVALUATED IN PEOPLE WITH MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE. THIS TRIAL IS BEING CONDUCTED TO: -EVALUATE THE SAFETY OF DIFFERENT DOSES OF MK-1942. -TEST THE EFFICACY OF DIFFERENT DOSES OF MK-1942 COMPARED TO PLACEBO.
Technical Summary
- PHASE 2A/2B, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF MK-1942 AS ADJUNCTIVE TREATMENT IN PARTICIPANTS WITH MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE.
- Code EudraCT: 2021-006336-94
- Protocol number: MK-1942-008
- Promoter: Merck Sharp & Dohme, S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.